Search - tctmd.com

Displaying 161 - 180 of 451

Sort: Relevancy | Date

News Daily News

Skipping Low-Value Cardiovascular Care Could Save Billions: AHA

Michael O'Riordan

March 01, 2022

News Conference News STS 2022

Tricuspid Repair During Mitral Valve Surgery Prevents TR Progression

Michael O'Riordan

February 04, 2022

News Conference News STS 2022

Modified Surgical MV Repair Stands Up to Replacement

Michael O'Riordan

February 03, 2022

News Conference News STS 2022

Bicuspid SAVR Outcomes Meet or Beat Tricuspid in STS Database

L.A. McKeown

February 02, 2022

News Conference News THT 2022

REDUCE LAP-HF II: Atrial Shunt Device Comes Up Short in HFpEF

Shelley Wood

February 01, 2022

News Daily News

PASCAL Pinpoints Patients With Strokes Causally Related to PFO

Yael L. Maxwell

December 20, 2021

News Conference News AHA 2021

Lariat LAA Ligation Doesn’t Boost Effect of AF Ablation: aMAZE Trial

Todd Neale

November 18, 2021

News Conference News AHA 2021

Tricuspid Repair During Mitral Surgery Slows Disease Progression at 2 Years

Caitlin E. Cox

November 13, 2021

News Conference News AHA 2021

AVATAR Supports Early SAVR in Asymptomatic Severe AS Patients

L.A. McKeown

November 13, 2021

News Opinion Editor's Corner AHA 2021

AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More

Shelley Wood

November 08, 2021

News Conference News TCT 2021

Transcatheter Mitral, Tricuspid Valve Replacement Inch Forward

Yael L. Maxwell

November 06, 2021

Presentation TCT 2021

SWISS-APERO: A Randomized Trial of the Amulet Versus Watchman FLX Devices for Left Atrial Appendage Closure

Presenter: Roberto Galea

November 06, 2021

Presentation TCT 2021

PARTNER 3: Two-Year Economic Outcomes From a Randomized Trial of TAVR vs. SAVR in Patients at Low Surgical Risk

Presenter: David Cohen

November 05, 2021

Presentation TCT 2021

SURTAVI: Five-Year Results From a Randomized Trial of TAVR vs. SAVR in Patients at Intermediate Surgical Risk

Presenter: Nicolas Van Mieghem

November 05, 2021

News Conference News TCT 2021

SURTAVI: Self-Expanding TAVI Valve Holds Up vs SAVR Through 5 Years

Todd Neale

November 05, 2021

News Daily News

Tailored TAVI: Standardizing Balloon Pressures May Curb Operator Angst

L.A. McKeown

October 28, 2021

News Daily News

Good TAVI Outcomes in Young Patients, but Population Is Unique

Michael O'Riordan

October 22, 2021

News Conference News EACTS 2021

More Deaths With Bioprosthetic Than Mechanical AVR in Young AS Patients

Michael O'Riordan

October 18, 2021

News Daily News

Half-Dose DOAC May Be a Good Post-Watchman Option

Todd Neale

October 14, 2021

News Conference News TCT 2021

LAA Closure Feasible in Patients With Thrombus: Registry

Michael O'Riordan

October 13, 2021

Advertisement

Skipping Low-Value Cardiovascular Care Could Save Billions: AHA

Tricuspid Repair During Mitral Valve Surgery Prevents TR Progression

Modified Surgical MV Repair Stands Up to Replacement

Bicuspid SAVR Outcomes Meet or Beat Tricuspid in STS Database

REDUCE LAP-HF II: Atrial Shunt Device Comes Up Short in HFpEF

PASCAL Pinpoints Patients With Strokes Causally Related to PFO

Lariat LAA Ligation Doesn’t Boost Effect of AF Ablation: aMAZE Trial

Tricuspid Repair During Mitral Surgery Slows Disease Progression at 2 Years

AVATAR Supports Early SAVR in Asymptomatic Severe AS Patients

AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More

Transcatheter Mitral, Tricuspid Valve Replacement Inch Forward

SWISS-APERO: A Randomized Trial of the Amulet Versus Watchman FLX Devices for Left Atrial Appendage Closure

PARTNER 3: Two-Year Economic Outcomes From a Randomized Trial of TAVR vs. SAVR in Patients at Low Surgical Risk

SURTAVI: Five-Year Results From a Randomized Trial of TAVR vs. SAVR in Patients at Intermediate Surgical Risk

SURTAVI: Self-Expanding TAVI Valve Holds Up vs SAVR Through 5 Years

Tailored TAVI: Standardizing Balloon Pressures May Curb Operator Angst

Good TAVI Outcomes in Young Patients, but Population Is Unique

More Deaths With Bioprosthetic Than Mechanical AVR in Young AS Patients

Half-Dose DOAC May Be a Good Post-Watchman Option

LAA Closure Feasible in Patients With Thrombus: Registry

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content